Pro resolving inflammatory effects of the lipid mediators of omega 3 fatty acids and its implication in SARS COVID-19.

Autor: Regidor PA; Exeltis Healthcare, Adalperostr. 84, 85737 Ismaning, Germany. Electronic address: pedro-antonio.regidor@exeltis.com., Santos FG; Solutex SA, Avenida de la Transición Espanola 24, 28108 Alcobendas, Spain. Electronic address: fgsantos@solutexcorp.com., Rizo JM; OTC Chemo, Manuel Pombo Angulo 28- 4th floor, 28050 Madrid, Spain. Electronic address: josemiguel.rizo@chemogroup.com., Egea FM; Solutex SA, Avenida de la Transición Espanola 24, 28108 Alcobendas, Spain. Electronic address: fmoreno@solutexcorp.com.
Jazyk: angličtina
Zdroj: Medical hypotheses [Med Hypotheses] 2020 Dec; Vol. 145, pp. 110340. Date of Electronic Publication: 2020 Oct 08.
DOI: 10.1016/j.mehy.2020.110340
Abstrakt: COVID-19 is a new disease caused by coronavirus SARS-CoV-2. It was first described in 2019, developed into an epidemic in January 2020 and has spread the global to the present COVID-19 pandemic. Specialized pro‑resolving mediators (SPMs) may play a new role in the management of this lung disease because SPM actively stimulate the resolution of infectious inflammation and are organ protective in animal disease models. Many tissues have been suitable targets for treating inflammation with SPMs or their active precursors 18-HEPE, 17-HDHA and the 14-HDHA, in order to elicit dynamic resolution of inflammation. Here we discuss the possible mode of action of these substances in the management of SARS Covid 19.
(Copyright © 2020 The Authors. Published by Elsevier Ltd.. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: